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1. Introduction
The development of the nervous system, neuralization of ectodermal cells, specification of cell
types as well as generation of neurological diseases are closely linked to Smad proteins, which
play a central role by integrating TGFβ and BMP signalling with other essential pathways. Due
to new findings on Smad activity in neurons and the nervous system, which comprises new
roles for brain plasticity and functions, independent of the canonical signalling pathways, we
reconsider their relevance for neuronal differentiation and dedifferentiation processes and as
therapeutic targets for treatment of neurological diseases. In this chapter we develop a view
at Smad molecules, which attributes them a basic significance and allow proving their specific
contextual molecular, cellular and tissue relationships. In order to facilitate the understanding
of the complex Smad network in the nervous system an overview of the canonical Smad
signalling pathway is briefly summarized in the following paragraph.
Smads are phylogenetic old proteins, which are mediating intracellular signalling of the large
group of solube TGFβ ligands (Figure 1), containing transforming growth factor βs (TGFβs),
bone morphogentic proteins (BMPs), growth and differentiation factors (GDFs), Müllerian
inhibitory factors (MISs), activins and inhibins [4]. Ligand binding to activated heteromeric
receptor complexes, recruited from seven type I and five type II serine/threonine receptors,
results in the specific phosphorylation of receptor-associated Smads (R-Smads) at two C-
terminal serine residues.
Activin, nodal and TGFβ activate R-Smad2 and 3, while BMP acts by R-Smad1,5 and 8
phosphorylation. In the cytoplasm non-phosphorylated R-Smads are sequestrated by inter‐
acting with specific retention proteins e.g. SARA (Smad anchor for receptor activation) [5],
endofin [8], tubulin [3], actin, myosin [11] or filamin [12]. Inhibitory Smad(I-Smad)6 and 7
negatively regulate R-Smad signalling by competing for binding to activated type I receptor
and inhibiting R-Smad phosphorylation. I-Smads can also prevent R-Smad complexing to the
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co-operating Smad(Co-Smad)4, which is required for the nuclear translocation of activated R-
Smads to subsequently control Smad sensitive promoter activity. Moreover, I-Smads support
recruitment of HECT-type E3-ubiquitin ligases Smurf1/2, which allow type I receptor ubiqui‐
tination and its degradation. Members of HECT-type and RING-type E3 ubiquitin ligases have
also been implicated in Smad degradation [13]. Regulating Smad activity allows the control of
highly complex developmental networks, e.g. the patterning of ventro-lateral mesoderm, the
decisive development of epidermal/neural cell lineages including the induction and estab‐
lishment of neural plate border, the dorso-ventral patterning of the neural tube, or the
migration of neural crest cells [18-21].
Figure 1. Synopsis of canonical Smad signalling. The upper panel shows the binding of ligands belonging to the
TGFβ superfamily to their serine/threonine kinase receptors types I and II, leading to intracellular activation of R-
Smads by receptor type I induced phosphorylation of the C-terminal Smad motif SSXS. The left and right receptor
complexes represent the TGFβ/activin/nodal linked Smad2/3 signalling and the BMP/GDF linked Smad1/5/8 signal‐
ling, respectiviely. The middle panel also displays a set of relevant binding partners of Smad proteins and shows the
generation of heterotrimer or heterodimer Smad complexes consisting of C-terminally phosphorylated R-Smads and
Co-Smad4, which are transported into the nucleus to excert their transcriptional activity by binding to susceptible pro‐
moter sequences (a). In (b) and (c) examples of the agonist-induced Smad linker phosphorylation mediated by cyclin-
dependent kinases are shown, which increases Smad transcriptional activity prior to signal termination and Smad
degradation [14, 17]. In contrast, the MAPK triggered linker phosphorylation of Smads in cytoplasm diminishes the
receptor type I responsible Smad phosphorylation and favours the cytoplasmic retention and degradation of Smad.
More information is provided in the main text.Note: Numbers in square brackets indicate relevant references included
in the reference list provided at the chapters end.Abbreviations: CDK, cyclin-dependent kinase; dynein, dynein light
chain km23-1 or km23-2; MAPK, mitogen activated protein kinase; MT, microtubuli; Nedd4L, neuronal precursor cell
expressed developmentally down-regulated 4-like ubiquitin ligase; Nuc214, nucleoporin 214; SARA, Smad achor for
receptor activation; Smurf1, HECT-domain ubiquitin ligase Smurf1.
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In R-Smads a linker region, located between the highly conserved N-terminal MH1- and the
C-terminal MH2 region (MH represents Mad homology), is rich in potential serine/threo‐
nine phosphorylation sites. Several kinases (e.g. MAPK, GSK, CDKs, CamKII, SGK1) can
phosphorylate the linker region and determine cellular distribution or protein stability of
Smads [14,23-26]. Linker phosphorylation by mitogen-activated protein kinases (MAPKs) re‐
stricts Smad1 activity by enabling Smurf1 binding, causing polyubiquitination and inhibit‐
ing interaction of Smad1 with nuclear transclocation factor Nup214, thus leading to Smad1
degradation or cytoplasmic retention [15].
A similar mechanism acts on Smad2 and 3, where ubiquitination is controlled by ubiquitin
ligase Nedd4L [17]. A sustained MAPK activation, as reported from dissociated embryonic
ectodermal cells, phosphorylates Smad linker and interrupt a continuing BMP mediated
Smad1 signalling finally resulting in neuralisation of dissociated Xenopus [27]. Remarably, if
linker phosphorylation is performed by extracellular signal regulated kinase (Erk) at nuclearly
localized phosphorylated Smad, the duration of Smad targeted gene transcription can be
increased [28]. Linker phosphorylation by CDK8 and CDK9 promotes both, the Smad tran‐
scriptional action, and the cooperation with YAP, an effector of the Hippo organ size control
pathway, to finally suppress neural differentiation of stem cells [14]. The data demonstrate the
particular role of the linker region for distinct Smad functions.
Numerous Smad binding proteins (e.g. Ski, SnoN) effectively influence essential steps during
neural development mostly by repression of Smad activity [29-33]. The group of Smad
interacting proteins (SIP), containing several zinc finger proteins, complex to Smad and can
directly or indirectly regulate its transcription efficiency [34]. For example, the induction of
neuroectoderm is dependent on SIP1 [35-37], which is also involved in the myelination process
and the oligodendrocyte maturation [38].
2. The role of Smads during neural/non-neuronal development
2.1. Already early development requires Smad expression
During early ontogenesis, development and aging as well as prior to individual cell death
Smad proteins differentially affect cellular function, depending on time and local partners.
Already at very early stages of postnatal rat development Smads1-7 were detectable in the
ovary [39]. At all stages of follicular development (e.g. in primordial, primary and secondary
follicles) Smad proteins are present in oocytes as well as in granulosa cells and theca cells,
though with different concentrations [39-41]. While Smad3,6 and 8 content did not change, the
expression of Smad1,2,4,5,6 and 7 seems to be regulated in ovary [39]. In mice oocytes a clear
and persistent nuclear localization of phosphorylated Smad1,5,9 and Smad2,3 demonstrates
activated activin/GDF9/nodal/TGFβ and BMP/MIS pathways, respectively, and confirms
oocytes as a major target for Smad signalling pathways [42]. Smad proteins play also important
roles already during maturation of human oocytes [43]. In unfertilized oocytes, Smad2 and 3
and TGFβ receptors I and II are present [44]. After fertilization at the 4-cell and 8-cell stages
Smad2 and 3 are also present, while neither of the TGFβ receptors is detectable. Later on in
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the blastocyte stage Smad2 and 3 kept present and TGFβ receptor I again appears [44]. Human
granulosa cells express Smad1-7 and 9, but Smad2,3, and 4 with the highest expression levels
[45]. A mutual interaction between oocytes and granulosa cells is necessary for normal
folliculogenesis. However, if Smad4 is deleted in granulosa cells infertility results, while
deletion of Smad4 in oocytes only marginally effects the primordial follicle stage [46]. How‐
ever, Smad2 reduction in zebrafish oocytes completely blocks activin A-induced oocyte
maturation and a Smad2 knockdown decreases basal and hCG-induced oocyte maturation
demonstrating a key role of Smads during oocyte maturation [47].
2.2. Gastrulation and neurulation
2.2.1. Suppression of Smad signalling specifies neuroectoderm generation
Initially, the ectoderm cells in Xenopus are pluripotent until gastrulation [48]. Early gastrula‐
tion steps are characterized by the formation of mesenchymal cells and the induction of
mesoderm in the marginal-zone by an epithelial-to-mesenchymal transition (EMT) process,
which involves activation of Smad2,3,4 signalling by TGFβ/nodal ligands after binding to
corresponding receptors [49-53].
Mesoderm induction requires a subtle coordination of the canonical TGFβ/nodal signalling,
with Smad4 as a key player. However, initially it was shown, that a simple ectopic Smad4
expression in the Xenopus animal cap was inefficient to induce mesoderm [54], due to its
binding to ectodermin, a RING-type ubiquitin ligase, which is highly expressed in the animal
cap [53]. Ectodermin limits Smad4 function via antagonizing nuclear accumulation of Smad4
and supporting Smad4 degradation by ubiquitin-proteosome pathway [53]. By this, ectoder‐
min ensures that ectoderm cells do only develop to a mesodermal lineage, but also supports
neural differentiation of ectoderm towards neuroectodermal fates by interfering with BMP
signalling via limiting Smad4 function [53]. However, the stable presence of soluble BMP
which prevents the execution of an intrinsic program of ectodermal cells to form neural tissue
can also be undermined by the release of BMP antagonists as noggin, chordin, follistatin or
cerberus, which however, allows creation and development of neural cells. This interrelation
is basically reflected in the ´default model´ of neural induction [55,56]. Confirming this model
it was shown, that the simultaneous depletion of BMP2, BMP4 and BMP7 induces massive
brain formation [57]. Accordingly, during early gastrulation-stage of chick embryo Smad1,5,8
signalling is undetectable [21] but is activated at neurula stage. So, phosphorylated Smad1
becomes detectable only at late gastrulation stages in the posterior territory of the embryo [21].
The default model has been further modified due to experiments showing that inhibition of
BMP/Smad1 signalling, e.g. by Smad6, was insufficient to induce neural markers efficiently
[58], while the additional suppression of Smad2 was sufficient [59]. Moreover, stimulation of
Smad2 signalling blocks neural induction even at gastrula stages and indicate prospective
neural cells to further undergo mesodermal and non-neural fates [59]. These data are sup‐
ported by experiments in sea urchin embryos showing that Smad2 and 3 suppress neural
differentiation in the oral ectoderm [60].
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Remarkably, conversely, it has also been suggested from very early studies on Smad2+/-;
Smad3-/- mutants in zebrafish showing anterior truncations [49], that Smad2 and Smad3, which
are mainly effectors of TGFβ/nodal pathways, are also positively involved in neural develop‐
ment [61]. Dominant negative Smad3 mutants inhibit the expression of early neural markers
sox2 and sox3 at the onset of gastrulation and lead to reduction of anterior and posterior
neuroectodermal markers otx2 and hoxb1b, respectively, during late gastrulation. According‐
ly, elevated Smad2 and Smad3 activities increased sox2 and sox3 expression, probably at least
partly due to its positive impact on chordin expression, which is a BMP antagonist [61]. In
mouse embryo BMP signalling also inhibits premature neural differentiation, but in contrast
to Xenopus [62] and chick [63,64] FGF signalling seems additionally required to induce neural
differentiation [65].
In summary, the data indicate that simultaneous suppression of both Smad1,5,8 and Smad2,3
pathways, e.g. suppression of mesoderm- and ectoderm-inducing Smad signals, respectively,
are required for neural induction. In principle, the `dual Smad inhibition` method is adopted
for induction of efficient neuralization of human (-induced) pluripotent stem cells (hiPSCs,
hPSCs) [66,67].
2.2.2. Neural tube closure
To establish a precise borderline between neuroectoderm (containing low BMP2/4 levels) and
non-neuroectoderm (containing high BMP2/4 levels) regions during early neurulation, specific
strategies are required and examined in urchin embryos, where Fez, a zinc finger protein, drops
down the BMP controlled pSmad1,5,8 levels [68]. It is probable that Fez acts as a transcriptional
repressor of Smad or interferes with genes attenuating intracellular BMP signalling e.g. SIP1,
Smurf1, Ski or SnoN.
Once the neuroectoderm forming is initiated a flat neural plate rolls up, the process of neural
plate folding proceeds and is finished by neural tube closure [69]. The closure of neural tube
is a complex process involving hinge points (HP), representing specialized neural plate cells.
The cells of ventral midline/median hinge point (MHP) as well as both dorso-lateral hinge
points (DLHPs) are affected by dynamic BMP signalling [70-73]. Folding of neural plate is
connected with a two-dimentionally spatiotemporal gradient of phosphorylated Smad1,5,8
(pSmad1,5,8) [71,73]. While initially a mosaic labelling of pSmad1,5,8 was observed at the
apical surface of the presumptive neuroectoderm later two intersecting Smad gradients were
exerted: a lateromedial gradient with the lowest pSmad1,5,8 expression at the MHP and a
second gradient along the apicobasal axis of the presumptive midbrain plate with mosaic
expression in apical nuclei [71]. Some of the apical pSmad1,5,8 positive cells proliferate and
thus support the neural fold elevation [71]. Disturbances of the phosphorylation state of
Smad1,5,8 alter midbrain shape by multiple hinge-like invaginations but do not affect the
ventral cell-fate specification [71]. However, the extent of Smad1,5,8 phosphorylation seems
to control MHP formation during neurulation in vertebrates. The correct MHF formation is
obviously directly linked to the pSmad1,5,8 controlled regulation of apicobasal polarity of
neural plates cells. After phosphorylation, Smad1,5,8 interact with the PAR3-PAR6-aPKC
complex and stabilizes linked tight junctions, while inversely low pSmad1,5,8 phosphorylation
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supports re-arrangement of neural plate cells, a prerequisite for MHP formation and neural
fold elevation [72].
2.2.3. Patterning and developing of the spinal cord
After closure, the neural tube starts to develop the spinal cord pattern along its dorso-ventral
axis which is essentially established by the expression of Wnt and BMPs, the main roof plate
morphogens, and sonic hedgehog (SHH) and TGFβs, the morphogens released from the floor
plate [74-76]. On the basis of provided intricated morphogenic gradients functionally distinct
neurons are generated.
Both roof plate derived BMP6 and BMP7 are evoking Smad1,5,8 phosphorylation and
subsequent induction of distinct dorsal interneurons (dI) via BMP receptor I activation [77-79].
While the BMP7/pSmad1,5 activated induction of dI1, dI3 and dI5 is independent of the
patterned expression of progenitor proteins, e.g. Pax7, Gsh1/2 or Olig3, a Smad regulated
expression of specific proneural proteins, e.g. cAth, and cAscl1, is required [79]. The patterning
of dorsal progenitor proteins could be associated with other BMPs, e.g. BMP4 [80]. Smad1 and
Smad5 activity seems to be important for the maintenance of neural cells as committed
progenitors, because the loss of Smad1,5 reduced the total number of newly generated neurons
and forces cell cycle exit and premature neurogenesis of neural progenitors [79]. The inhibitory
Smad6 also promotes the neuronal differentiation in the spinal cord by interfering with Wnt-
signalling [81]. Hazen and colleagues demonstrated, that the inhibitory Smad6 and Smad7
function to restrict the action of roof plate released BMPs to distinct dorsal interneurons and
participate in the determination of dI4-dI6 spinal neuron number [82].
However, the subsequent orientation of spinal neurons is also controlled by BMP7 but not via
activation of Smad signalling instead using phosphoinosite-3-kinase (PI3K) activation by the
BMP receptor type II [77]. Nevertheless, Smad6 most potently allows blocking dI1 axon
outgrowth [82].
While Smad3 was also expressed in the developing spinal cord, Smad2 was not detected [83].
Contrasting to Smad1,5,8, the expression of Smad3 in the developing spinal cord depends on
progenitor proteins, e.g. Nkx6.1, Olig2, Nkx2.2, which directs the Smad3 expression mainly to
discrete ventral progenitor domains [83]. Smad3 activity in turn reduces expression of
progenitor proteins and promotes activation of neuronal differentiation, e.g. by supporting
cell cycle exit via activating of p27Kip1 expression [83]. The Smad3 expression is sufficient to
promote differentiation of ventral and various dorsal interneurons, while differentiation of
motor neurons is impaired. Therefore Smad3 expression is excluded in the prospective motor
neuron progenitor cells [83].
2.2.4. Induction of neural crest (NC)
Multipotent embryonic cells of the dorsal region of the neural tube, an area existing immedi‐
ately before forming the neural plate border (NPB), are the origin of neural crest cells (NC)
that migrate to initiate a panel of diverse derivatives including various non-neural but also
neural cells e.g. sensory neurons of the peripheral nervous system. The combination of several
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signalling pathways is required [84] for a timely and locally well tuned progression. Besides
Wnt signalling a major role in NC induction plays canonical BMP signalling [85-90] combined
with FGF signalling [21,91]. The inductive step of NPB development during gastrulation
requires a concerted action of activated Wnt signals and inhibition of BMP signalling repre‐
sented by low Smad1,5,8 activity. Later, when neurulation proceeds and NC develops from
NPB, activated Wnt signals cooperate with a robust Smad1,5,8 activation in NPB. While during
the inductive step of NC gastrulation FGF downregulates Smad1,5,8 activity by triggering
MAPK, the catalysed phosphorylation of Smad1,5,8 linker region is nearly completely absent
in NPB during neurulation. In consequence, a strongly elevated Smad1,5,8 signalling is
observed suggesting a ´two step model of NC development´ with respect to activated
Smad1,5,8 signalling [21].
2.3. Peripheral nervous system (PNS)
The further outcome of NC cells including the generation of the PNS also strongly depends
on Smad signalling. Interestingly, Smad expression regulates both the formation of neurons
of PNS as well as early stages of peripheral glial development.
Precursors that emigrate from the neural crest to the bowel generates the enteric nervous
system (ENS) belonging to PNS. If fetal enteral neural crest-derived cells (ENCDC) of gut are
exposed to BMP2 or BMP4 phosphorylated Smad1 translocates to the nucleus and the cells
develop processes, indicating an essential role of Smad phosphorylation for neuron induction
in the gut [92]. However, Smad phosphorylation alone is not sufficient to direct development
of ENCDC towards ENS neurons or glial cells but requires further factors e.g. glial growth
factor 2 (GGF2) [93]. Moreover, besides generation, also maturation of enteric neurons (as well
as regulation of gliogenesis) during postnatal development is Smad-dependent. This function
was identified because mice lacking in the homeodomain interacting protein kinase 2 (HIPK2),
which can interact with Smad1, Smad2 and Smad3 [94] and therefore control transcription of
subsequent Smad-dependent promoters, are characterized by a progressive loss of enteric
neurons and an arrest in synaptic maturation postnatally. Additionally, in the HIPK2-/- mice
the remaining enteric neurons exhibit an increased number of cells with nuclear Smad1,5,8
phosphorylation [95]. Interestingly, both in the enteric nervous system and in the midbrain
[96], HIPK2 reduction severely reduces survival of dopaminergic neurons through interfer‐
ence with Smad signalling pathways, regulated by BMP2/4 or TGFβ, respectively. Whether
altered Smad signalling, affected by HIPK2, is also responsible for Parkinson´s disease and
would allow to develop a therapeutic intervention has to be investigated in the future.
Recent data demonstrate, that Smad1 signalling by BMP2 induction is implicated in differen‐
tiation of primary enteric neurons to catecholaminergic (TH expression) but not to cholinergic
(ChAT expression) neuronal subtypes [97].
Peripheral glia precursors derived from neural-crest and exhibiting characteristic expression
of immature glia markers e.g. nestin, are critically influenced by BMP2/Smad signalling. Using
Smad1 activation, neural-crest precursor cells, that begin to develop along glial pathway are
kept in an undifferentiated immature multipotent state, thus allowing migration to their
postmigratory locations [98] where they later acquire myelinating properties. Smad-linked
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activation of GFAP promoter is part of this process [99]. Generally, oligodendroglial differen‐
tiation of precursor cells is actively suppressed by BMPs concomitant with the stimulation of
astrocytic differentiation [100]. Accordingly, BMP4-activation directs progenitor cells in vivo
to commit to the astrocytic rather than the oligodendroglial lineage [101].
3. Specific cell types and the role of Smad expression for their induction
and maintenance
3.1. Cell type decision, maturation and differentiation
Both generation and differentiation of neurons in the brain (CNS) comprises several different
and complex principles. The initial proliferation of neural precursor cells is followed by the
decision to specify neuronal or glial outcome. Afterwards, the primary neurogenesis of
neuronal progenitors involves migration, settlement and stopping proliferation by cell cycle
exit to enter a terminal differentiation pathway. Many of these basic biological routes as well
as further differentiation steps, e.g. dendritic and axonal growth and orientating, synapse
formation and myelination depend on Smad proteins. The parallel occurrence of long term
and acute Smad-dependent processes require a distinct contextual organisation. For example,
in the developing brain an important neural stem cell is provided by radial glia cells which
can generate both glial cells and neurons. While TGFβ promoted differentiation of radial glia
into astrocytes is mainly regulated by activation of MAPK signalling, neurogenesis is control‐
led by the interplay of Smad2,3 activity and PI3K activity [102].
3.1.1. Glial cells
Radial glial cells can function as neuronal precursors and also control migration of neurons
during cerebral cortex development [103]. Developing neurons are also actively implicated in
the radial glial cell fate commitment [104]. Using TGFβ release, neurons can activate Smad
signalling in radial glia cells and support their transformation to astrocytes [105] and also
induces astrocytic differentiation and GFAP expression [106-109].
Moreover, endothelial cells also promote astrocytic differentiation by BMP-induced Smad
signalling, but inhibit oligodendrocyte differentiation of postnatal cortical progenitors [110],
and therefore participate in the sequential order of the two macroglial cell gliogenesis. The
function of BMP/Smad signalling to drive precursors to astrocytic fate seems a common feature
[111,112] which is also involved in CNS injury processes where oligodendrocyte precursors
are driven towards type II astrocytes [113]. Accordingly, inhibition of BMP induced nuclear
translocation of phospho-Smad1 by FGF2 activated MAPK activity is linked to Smad4
dissociation from Olig2 promoter and results in upregulation of oligodendrogenesis [114]. The
very importance of a spatially and temporally regulated BMP induced Smad activation for the
fate of neurogenic precursor cells was shown in chick spinal cord. At embryonic day 5, in
neuroepithelial progenitors, astrocyte marker expression was inhibited and at embryonic day
6 it was promoted initiating a gliogenic period [115].
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3.1.2. Neurons
The commitment of cell fates in the nervous system is strongly dependent on Smad2,3
signalling cascade. However, there have been contradictory results on the role of Smad3 for
neuronal precursor proliferation and their differentiation, indicating a complex Smad signal‐
ling network dependent on local, temporal and contextual characteristics.
Some reports show, that TGFβ, which activates Smad3 signalling, diminishes neurogenesis in
hippocampus after its chronical increase [116], and in SVZ and DG after intracerebroventric‐
ular TGFβ1 infusion [117] and promotes neuronal differentiation from hippocampal and
cortical progenitors [118]. An clear inhibitory function of Smad3 on neural precursor prolif‐
eration was shown in the developing spinal cord [119], where Smad3 also promotes differen‐
tiation and influences the fate of selected neurons. The antiproliferative role of Smad3 and
Smad4 plays a role during early-postnatal differentiation of cerebellar neurons into postmitotic
neurons, where TGFβ stimulation induces nuclear translocation of phosphorylated Smads and
induction of cyclin-dependent kinase inhibitors p21, p27 and markers of neuronal maturity
[120].
However, other reports show that TGFβ increased neurogenesis in DG after adrenalectomy
[121] or in SVZ after stroke [122].
To clarify the relevance of Smad3 for adult neurogenesis Smad3 null mice were studied
[123,124]. These mice show decreased neurogenesis in the DG and the SVZ and exhibit a
thinner and more disorganized rostral migratory stream (RMS) of neuronal precursor cells
(NPC). Using RMS NPCs migrate from SVZ to reach the olfactory bulb, where they differen‐
tiate into granular and periglomerular neurons. Though a decreased number of proliferating
cells demonstrates the requirement of Smad3 for maintaining a proper cell division rate in
SVZ, the neuronal fate is not altered by Smad3 deficiency [123].
For differentiation of mesencephalic progenitors into dopaminergic (DA) neurons a concerted
interaction of Smad2,3 signalling and p38 MAPK-pathways by TGFβ receptor stimulation is
necessary. Accordingly, treatment of ventral mesencephalic neural progenitors with TGFβ
increased the number of tyrosine-hydroxylase (TH)-positive cells [125]. Though not required
for the neurogenesis, the survival of midbrain dopaminergic neurons depends on function of
the homeodomain interacting protein kinase 2 (HIPK2), which interacts with R-Smads to
activate TGFβ responsive genes [96]. Loss of HIPK2 increases apoptosis in DA neurons during
development. Nevertheless, apoptosis of specific neural progenitors during neural differen‐
tiation also involves Smad phosphorylation as shown for Smad1,5,8 [126,127].
In vitro, treatment of ventral mesencephalic cells with BMP5,6 and 7 also significantly
increased the number of TH-positive neurons via Smad phosphorylation and nuclear trans‐
location [128], while the neurotrophin growth/differentiation factor 5 (GDF5) induced Smad
pathway promotes neuronal but not dopaminergic differentiation [129]. Remarkably, the in
vitro generation of functional dopaminergic substantia nigra neurons for transplantation
requires a protocol which uses the temporarily and contextually distinct roles of Smad
proteins: Firstly, the dual inhibition of Smad signalling in embryonic stem cells is required to
allow induction of floor plate cell state which then passes over to midbrain floor plate cell state.
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Secondly, an activation of Smad signalling using TGFβ pathway is necessary to finally obtain
dopaminergic neurons suitable to threat Parkinson´s like symptoms [130].
In the developing cerebellum, Smad1 is expressed in the external germinal layer and Smad5
is synthesized in newly differentiated granule neurons. In the granule precursor cells, Smad5
overexpression is sufficient to initiate differentiation [131]. In mice lacking Smad4, a decreased
number of cerebellar Purkinje cells and parvalbumin-positive interneurons [132] is found
while no alterations of proliferation of neuronal precursor cells were detectable. Loss of Smad4
also reduces differentiation of noradrenergic neurons [133].
Basal forebrain cholinergic neurons are essentially involved in the organisation of cortical brain
structures, learning and memory. Smad1-5 are expressed in basal forebrain from embryonic
day 14 to the adult age [134]. An intact canonical TGFβ/Smad2,3 cascade is important for the
function of cholinergic neurons. Smad signalling mediates rapid inhibition of calcium influx
in cholinergic basal forebrain neurons [135]. The sleep/wake circadian rhythm controlled by
cholinergic neurons of the pedunculopontine nucleus (PPT) is also dependent on phosphor‐
ylation levels of Smad2 and Smad3. Overactivation of Smad2,3 signalling resulting in increased
nuclear translocation is linked to sleep/wake circadian rhythm amplitude deficits [136]. BMP9
driven Smad1,5 phosphorylation and their formation of complexes with Smad4 are involved
in the induction of the cholinergic phenotype in the basal forebrain [134,137]. Moreover, only
in postmitotic cholinergic neurons, this pathway induces NGF expression, an autocrine/
paracrine cholinergic trophic factor, which stimulates ACh production [138]. Accordingly, it
is of therapeutic relevance for treatment of Alzheimer´s disease, that BMP9/Smad1,5 signalling
can prevent lesion-evoked impairment of the cholinergic septo-hippocampal neurons in adult
mice [139]. The basal forebrain cholinergic neuron specific gene expression pattern is also
basically linked to an interaction of Smad and Sizn1 (Smad-interacting zinc finger protein), a
factor which causes mental retardation if mutated [140,141].
3.2. Axon and synapse formation
Induction of axons and orienting of axon responses are controlled by several Smad molecules
of both the BMP and the TGFβ/activin pathways in a timely and spatially organized manner.
Several different neuronal/neural cell types use individual aspects of the Smad machinery.
3.2.1. Basic role of Smads for neuritic outgrowth
In PC12 cells, which are initially derived from neural crest cells and are used as model system
for neuronal differentiation, BMP2 induces neurite outgrowth [142] by activation of TAK1/p38
kinase signalling pathway [143,144], which is in turn tightly controlled by the simultaneous,
also BMP2-induced expression of the inhibitory Smad6 and Smad7 [142] performed via
activation of Smad1,5,8 pathway. The inhibitory Smads are considered to inversely inhibit
BMP signalling in a concerted action by repressing Smad1,5,8, mediating BMP receptor
degradation by Smurf1 [16,145], and by physical interaction with TAK1-binding protein,
which finally reduces the p38-mediated neuritic outgrowth [143,144]. Neurotrophin 3 induced
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neuritic outgrowth is potentiated by BMP4/6 induced phosphorylation of Smad1,5,8 and their
subsequent inhibition of MEK in chicken neurons [146].
Otherwise, BMP2 inhibits neuritic outgrowth and differentiation of motor neuron-like NSC-34
cells by activation of Smad1,5,8-dependent signalling and subsequent Id genes activation,
which are main targets of Smad signalling and which negatively regulate differentiation of
various cells including neurogenic precursors and motor-neuron precursors [147].
3.2.2. Subtle control of axonal morphogenesis
The axonal morphogenesis is strongly influenced by the TGFβ-regulated signalling protein
Smad2. Endogenous Smad2 is constitutively activated and its phosphorylated form is nucle‐
arly localized in human and mouse hippocampal and cortical neurons [148,149] and in primary
granule neurons of rat cerebellum [150]. In granule neurons Smad2 can form a physical
complex with the endogenous transcriptional modulator SnoN, which is also nuclearly
localized and strongly enhances axonal growth [151] and neuronal branching [152] by
regulating a large number of neuronal genes [153]. SnoN ubiquitination and degradation is
controlled by the nuclear ubiquitin ligase Cdh1-anaphase-promoting complex (Cdh1-APC),
which physically interact with nuclear SnoN thus suppressing axonal growth. [151,154].
Obviously Smad2 binding to SnoN facilitates the ability of Cdh1-APC to control SnoN
degradation. Consequently, if phosphorylation levels of Smad2 are reduced, SnoN levels
increased and axonal growth is stimulated which allow therapeutic potential after brain injury
[150]. The constitutive neuronal expression of axonal growth inhibitors e.g. Smad2, Smad3
[148] and Cdh1 [155] and the reduced expression of axon growth promoters (SnoN) in
terminally differentiated neurons [150] generate an intrinsic axon growth inhibition control,
allowing a balance between steady state and neuronal plasticity.
3.2.3. Axonal regeneration
Axonal regeneration requires the reversal of an age-dependent loss of intrinsic axonal growth
capability [156,157]. In dorsal root ganglion cells (DRG), which possess two branches of a
initially unipolar axon, (a) a central branch containing in the spinal cord and (b) a peripheral
branch innervating sensory targets, the axotomy of the peripheral branch requires function of
transcription factor Smad1 for successful regeneration [158]. While in embryonic DRG neurons
during the phase of active axon growth Smad1 RNA and protein were strongly expressed and
found abundantly C-terminally phosphorylated in the nuclei (while Smad8 expression was
low and Smad5 expression was concentrated to the periventricular zone), in adult DRG
neurons Smad1 phosphorylation was diminished [159]. However, after axotomy, the induction
and nuclear translocation of Smad1 precedes the onset of axonal extension and are maintained
over longer time, demonstrating the importance of Smad1 for the perpetuation of the activated
axonal growth program [158]. Interestingly, Smad1-dependent axonal growth program is an
intrinsic feature of DRG neurons which functions independently of extracellular BMP. Until
now, the detailed underlying mechanism for BMP-independent Smad1 phosphorylation is not
completely elucidated. It is possible, that endogenous cytoplasmic kinases or intracellularly
available BMP/BMP-receptor complexes might be involved. The ligand-independent C-
The Role of Smad Proteins for Development, Differentiation and Dedifferentiation of Neurons
http://dx.doi.org/10.5772/54532
85
terminal phosphorylation of the SSXS domain of Smad2 and Smad3 was already reported [160]
suggesting a possible extracellular ligand-independent universal strategy. Probably, Smad1
signalling is also involved in the axonogenesis of many other classes of neurons, e.g. Purkinje
cells, retinal ganglionic, olfactory and motor neurons which were already found positively
labelled for pSmad1 immunoreactivity [159]. Due to the possible linker phosphorylation of
Smad1 by several kinases (e.g. MAPK, GSK, CDK), the molecule might serve as an integrator
of various pathways relevant for axon growth and regeneration [14,23-26]. However, for
clinical and therapeutic relevance, the transduction of adeno-associated vector encoded BMP4
allows stimulation of Smad1 phosphorylation and activation of axonal growth independent
of axotomy and also promotes sensory axon regeneration after axotomy [159]. At least partly
BMP effects are dependent on its binding to repulsive guidance molecules [161].
While Smad1 positively supports axonal growth, the inhibitory Smad6 can block axon
outgrowth, as shown for post-mitotic dI1 axons of the spinal cord [82] and therefore exert roles
in spatially limiting the influence of BMP signalling on neurons.
In Drosophila, Smad2 is involved in motor neuron axon guidance, as null mutants of Smad2
exhibit axon guidance defects [162]. It is suggested, that a chemoattractant signal of TGFβ
superfamily members provided by muscle cells might guide motor axons to their appropriate
innervation sites.
3.2.4. R-Smads and Co-Smads exert neuronal plasticity
The development of peripheral tissues is connected to axonal growth of peripheral nerves,
linking sensory information to the spinal cord via neuronal cell bodies localized in ganglia.
After initial axon extension for trigeminal sensory neurons in mice, a Smad4-dependent
retrograde signalling from developing face to the neuronal nuclei was found, which control
the expression of genes in neurons of the trigeminal ganglion in dependence on their position.
Extrinsic signals released from developing craniofacial tissue, e.g. BMP4, activate phosphor‐
ylation of Smad1,5,8 at the axon terminals and selectively retrogradely signals this information
to selected trigeminal neuronal cell bodies thus inducing spacially patterned expression of
further transcription factors along the dorso-ventral axis of the trigeminal ganglion [163]. A
comparable retrograde mechanism based on dSmad2 was found in R7 axons in the Drosophila
visual system, where activin, secreted from the R7 cells growth cone in an autocrine manner,
activates its receptor and initiates intracellular Smad2 phosphorylation. The pSmad2 com‐
plexes to the nuclear import adaptor Importin-α3, shuttles to the nucleus and reduces growth
cone motility and synaptogenesis via transcriptional regulation of several target genes [164].
Already in Drosophila, a retrograde Smad-based signalling of the BMP homolog Gbb regulates
synaptic growth in presynaptic motor neurons [165]. The underlying mechanism for the
retrograde Smad-based signalling was recently examined for the BMP4 signalling system. Ji
and colleagues (2012) discovered that endosomes carrying the BMP-signalling complex
containing phosphorylated Smad1,5,8, are essentially linked to a BDNF-induced axonal or
growth cone translation of Smad proteins to retrogradely control transcription in trigeminal
neurons [166,167]. This `two-target-derived signalling´ integrates neurotrophin and BMP
signals on the level of Smad proteins, which are axonally translated on demand. This process
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is involved in the acquisition of positional identity markers during trigeminal ganglia devel‐
opment and selectively works in ophthalmic and maxillary but not in mandibular axons
obviously due to the failure of BDNF in the mandibular target field [166]. The underlying
mechanism suggests to re-evaluate the role and extent of Smad based transcriptional regula‐
tion. (1) Nearly all cellular surfaces/membranes, including dendrites, axons, growth cones and
spines might receive information which could be integrated by Smad signalling. (2) The
retrograde transport of other ligands of the TGFβ group was already reported, e.g. TGFβ2 in
normal and injured motor neurons [168], implicating the question whether axonal Smad
signalling is involved in injury-response. (3) The mechanism might work with all those
extracellular and also intracellular factors that affect Smad translation, and might at least partly
explain neurodegenerative disorders, which are characterized by disturbed axonal transport
and/or neurotrophin deficiency at neuronal terminals
The specific structure of axons and the axonal transport of Smad signals [166] as well as simple
translocation of receptor phosphorylated Smads from cytoplasmic receptor site into the
nucleus require intact microtubule network. Phosphorylated Smad2 is transported using
microtubules by support of kinesin-1 and kinesinATPase activity [169] and also requires
dynein light chain km23-1 [6], whereas pSmad3 transport was dependent on km23-2 function
[170]. Additionally retrograde axonal transport of phosphorylated Smads, which is necessary
for transition of axonal synaptic BMP-like ligand mediated phosphorylation of Smads in
Drosophila, also depends on an intact function of p150Glued protein. P150Glued is a compo‐
nent of the dynactin complex, which is necessarily involved in synapse assembly and stability
[171]. However, a p150Glued knockdown induced disruption of synaptic homeostasis can be
rescued by activation of Smad signalling at the soma [172,173], confirming the important role
of nuclear phosphorylated Smad to synaptic homeostasis.
3.2.5. Astrocytic and oligodenrocytic Smad signalling influences neuronal axonal growth
Astrocytes surrounding synapses are also target of neuronal activity. Glial metabotropic
glutamate 2/3 receptor activation by neuronally released glutamate induces astrocytic TGFβ1
secretion, leading to GFAP gene activation and astrocyte differentiation involving astrocytic
Smad signalling pathways [174].
Chondroitin sulphate proteoglycans (CSPG), mainly synthesized by astrocytes, can inhibit
axonal growth and regeneration. After traumatic brain injury or disruptions of the blood brain
barrier, mature or fibrinogen-coupled latent TGFβ is released into the CNS and increases the
CSPG expression by a Smad signalling manner in astrocytes [175,176]. Both astrocytic Smad2
and Smad3 expression and phosphorylation leads to inhibition of neuronal outgrowth and is
required for astrocytic neurocan synthesis, whereas phosphacan only requires Smad2
[175,176]. Reduced Smad3 levels selectively reduced induction of chondroitin-4- sulphotrans‐
ferase 1 and the amount of 4-sulfated CSPGs secreted by astrocytes and also promoted axonal
growth of neurons which were fed on these astrocytes [175]. Taxol treatment of astrocytes can
reduce CSPG expression by interfering with kinesin-1-dependent pSmad transport into the
nucleus [177] and improve axon regeneration after spinal cord injury.
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The Smad-interacting-protein 1 (Sip1) is an essential modulator for CNS myelination. In
oligodendrocytes, it functions in a dual-mode manner by repressing the differentiation
inhibitory signals of the BMP-receptor activated Smad1,5,8 activity [178] and activating
oligodendrocytes-promoting factors, thus controlling proper myelination in the CNS [38].
3.3. Smads contribute to synapse formation and synaptic transmission processes
Synapse formation and remodelling are results of intrinsic programs and environmental
insults. Synapses are characterized by close cell-to-cell communications, which also include
synaptic transmission and signalling processes mediated by growth factors e.g. members of
the TGFβ superfamily. In spinster a mutation of the inhibitory Smad Dad (Daughters against
dpp) causes synaptic overgrowth [179]. A well investigated synaptic system is the neuromus‐
cular junction (NMJ) of Drosophila, showing the involvement of Smad proteins in synapse
function both in pre- and in postsynaptic cells. The release of muscular BMP4-type ligand Gbb,
which is required for intact function of a large part of postsynaptic muscles [165], allows its
binding to a presynaptic receptor consisting of one type I and one type II receptor, Sax or Tkv
and Wit, respectively [180,181], and the subsequent phosphorylation of the R-Smad, Mothers
against dpp (Mad) [165]. Activated Mad is responsible for presynaptic nuclear propagation of
the postsynaptic muscular BMP signals and finally for regulating synapse growth, morphol‐
ogy and function of motor-neurons at least partly by altering transcription [165,180,182]. The
retrograde transport of Mad utilizes microtubule motor proteins, e.g. dynein complexes, and
is sensitive to disruption of dynein motor function [165]. The Drosophila Co-Smad/Smad4
homolog Medea (Med) is also necessary for presynaptic BMP signalling cascade and essential
for synaptic growth [183]. Both, Med and Mad mutants, exhibit defects in neurotransmitter
release and synaptic ultrastructure [165,183]. It is suggested that an equilibrium exist between
the binding of presynaptic phosphorylated Mad to Med and the binding of Med to the RING
finger E3 ubiquitin ligase Hiw [184], which regulate the synaptic growth in NMJ [183].
Additionally to the retrograde neuronal Mad/Med-mediated Gbb signalling, anterogradely
released TGFβ type ligands activate Mad phosphorylation at the postsynaptic density (PSD)
zone of postsynaptic muscles and NMJ depolarization supports Mad nuclear transition in the
muscles [185]. In summary, a mutual information flow of neuron and muscle on each phys‐
iological state and the synaptic cleft situation is essentially controlled by specific R- and Co-
Smad signalling in both cellular systems.
Importantly, the activation of Mad phosphorylation and nuclear translocation by the BMP
ligand Gbb directs the expression of synaptic homeostasis independently of synaptic growth
control in Drosophila [173]. However, retrograde transport of Mad, which was phosphorylated
at the periphery of the axon terminal due to synaptic Gbb binding, mediates synaptic homeo‐
stasis. Remarkably, Gbb induced phosphorylation of Mad at the soma site of the neuron
compensate for a disturbed retrograde axonal pMad transport completely [173]. The release
of muscular Gbb into the synaptic cleft at the periphery to activate neuronal retrograde pMad
transport, can be regulated by activin, which controls the muscular Gbb synthesis by recruiting
the Drosophila dSmad2 [186]. Cdc42-interacting protein 4 (dCIP4) which is also localized
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postsynaptically at the NMJs co-regulates the phosphorylation of neuronal Mad levels by
inhibiting postsynaptic Gbb secretion [187].
These data indicate, that both activin and BMP directed R-Smad signalling controls synaptic
function at NMJ and affects the development of synaptic homeostasis.
4. Role of Smads for neurological disorders
Several neurological diseases are characterized by disturbed cellular or subcellular Smad
localization and show artificial Smad sequestration or deposition. Especially in neurodege‐
nerative and motor neuron diseases a disruption of Smad controlled transcriptional machinery
was reported.
Neurodegenerative diseases are characterised by selective and progressive loss of specific
populations of neurones. Four disease-classes are proposed based on four major affected
proteins, tau, βA4-amyloid (βA4), α-synuclein and TDP-43, and therefore, neurodegenerative
diseases can roughly be classified into four main groups: amyloidosis, tauopathies, synuclei‐
nopathies and TDP-43 proteinopathies (for review see [188]). Recent data indicate, that in all
four disease groups Smad proteins are essentially involved in the disease progression, finally
indicating a remarkable commonness of these diseases.
4.1. Alzheimer´s disease
Alzheimer´s disease (AD), representing a mixture of both amyloidosis and tauopathy, is a
severe neurodegenerative disorder and the most common cause of dementia in the elderly.
Typical clinical symptoms are memory loss, disturbed activities of daily life and deficiency of
social competence. Common morphological correlates to the clinical features are extracellular
βA4-plaque depositions, intraneuronal tau pathology, neuronal cell death, and cell cycle
activation [189].
In AD, we identified a strong disturbance of the normal constitutive nuclear localization of
phosphorylated Smad2 and Smad3 in hippocampal and cortical neurons [148], which subse‐
quently was confirmed by others [190,191]. In AD brain, a strong colocalization of pSmad2,3
with intracellular neurofibrillary tangles (NFTs) in neurons and with βA4-amyloid plaques in
addition to a sequestration of pSmad2,3 in cytoplasmic granular vesicles is detectable [148].
Additionally a significant reduction of Smad2,3,4, which are involved in activation of cell cycle
proteins was described. Smad4 directly controls cyclin-dependent kinase 4 (CDK4) expression
in neuronal cells and is involved in cell cycle activation of neurons in AD brain [192]. It is quite
possible, that the recently identified TGFβ1-induced antiapoptotic factor (TIAF1), which can
bind and block Smad4-dependent promoter activation [193], participates in the cytoplasmic
Smad sequestration in AD neurons and suppresses Smad-regulated promoter activation.
Environmental stress or TGFβ1, can induce TIAF aggregation, which in turn removes soluble
Smad4, induces apoptosis and activates βA4 generation and its aggregation [193].
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A reason for the intraneuronal dislocation of Smads could be due to the disturbed nucleocy‐
toplasmic transport in hippocampal AD neurons [194,195]. The inner nuclear membrane
comprises integral proteins, e.g. MAN1, which regulate Smad phosphorylation and nuclear
translocation [196], while the outer nuclear membrane is directly continuous with the rough
endoplasmic reticulum. Both membranes are separated by nuclear core complexes, which also
control nucleocytoplasmic shuttling of Smad2 [197]. Altered nuclear membrane integrity [195]
might provoke misrouting of phosphorylated Smads into the associated ER compartment,
indicated by the co-localization of phosphorylated Smad2 granules with a luminal marker
protein of the ER, protein disulphide isomerase [148,198]. ER containing Smad2 could be
secreted and thus explain the extracellular association of pSmad2,3 with amyloid plaques
[148,190]. Alternatively, pSmad2 could interact in early endosomes with βA4-peptides which
are accumulating in the early stages of AD [199], and there also meet BACE, the β-secretase,
generating β-amyloid peptides [200], activated TGFβ receptors type I and II as well as SARA,
a Smad anchor for receptor activation [201-203]. It is also possible, that early endosomes can
fuse to the ER thus allowing a direct route of Smad proteins to the lumen of the ER [204,205].
However, activation of cell cycle is a hallmark of AD and (1) probably supports hyperphos‐
phorylation of tau protein which leads to generation of neurofibrillary tangles and (2) increases
neuronal apoptosis by phosphorylation of retinoblastoma protein and activation of E2F based
apoptotic impacts (for review see [206]. Hyperphosphorylation of tau affects the neuronal
Smad2,3 localization, diminishes its nuclear concentration and thus impedes with transcrip‐
tional Smad functions as shown after βA4 treatment of primary neurons [207]. NFT formation
in AD brain disturbs common intra-neuronal transport mechanisms [208]. This disturbance
could also interfere with retrograde Smad signalling which could be suggested for hippocam‐
pal neurons but so far has only demonstrated for Drosophila motor neurons [173]. Moreover,
we also suggest, that the principle of the two-target-derived signalling integrating neurotro‐
phin (BDNF) and Smad pathway found in rat trigeminal neurons [166,167] might also play a
role for AD progression, because BDNF is deficient in entorhinal cortex and hippocampus in
AD [209,210]. Finally, a disturbed nuclear Smad localization might influence competence of
neurons to express synaptic homeostasis and plasticity, both processes are well investigated
for Drosophila motor neurons.
Pathogenic reduction of neuronal Smads can also support activation of neuronal cell cycle,
resulting in neuronal apoptosis [211] e.g. by repression of cyclin-dependent kinase inhibitors
(CDIs) p15Ink4B, p16Ink4A, or p21Cip, which expression is controlled by TGFβ/Smad signalling
[212-214]. Though the increased levels of TGFβ1 in AD [215,216] does not seem to be able to
compensate for the compromised canonical neuronal Smad pathway [148,190], astrocytes were
shown responsive to this growth factor, which induces amyloid precursor protein (APP)
expression in cooperation with Sp1 [217] and CTCF [218]. Altered APP cleavage by the
concerted action of α-, β- and γ-secretases is a main aspect of AD pathology and results in the
generation of the pathogenetic βA4 peptide 1-42, which is neurotoxic and leads to βA4-amyloid
plaques. Whether βA4 peptide 1-42 can further suppress neuronal TGFβ1/Smad2,3 signalling
by activation of the inhibitory Smad7 in neurons as already shown for human monocytes
cannot be excluded [219].
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Clearance of βA4 peptide was reported by microglia cells [220]. TGFβ released by neurons or
astrocytes stimulates βA4 peptide uptake through Smad3-dependent increased scavenger
receptor SR-A expression and increased phagocytosis [221]. Though the microglial capacity to
remove βA4-plaques is limited [222], peripheral phagocytes, migrating into the brain if their
Smad2,3 signalling is blocked at the expense of Smad1,5,8 phosphorylation, might perform
this task successfully [223].
In other tauopathies, e.g. Pick disease, progressive supranuclear palsy, and corticobasal
degeneration, cytoplasmic phospho-tau bound pSmad2,3 was also identified, though reduced
nuclear pSmad levels were not found [224] suggesting a different impact on Smad signalling
in these diseases compared to AD.
4.2. Parkinson´s disease
Parkinson´s disease (PD) is a progressive neurodegenerative disorder which is characterized
by dopaminergic neurodegeneration in the substantia nigra (SN) pars compacta. The closely
associated loss of dopaminergic inputs into the striatum results in failure of motor programmes
(e.g. voluntary movements) and initiates a striatal plastic change [225,226]. The gradual loss
of dopaminergic neurons is linked to an increase of dopamine turnover [227,228]. α-synuclein
(α-syn) is the major protein component of Lewy bodies, a hallmark of PD. It can aggregate to
form toxic oligomers and fibrillar structures [226,229].
It was shown, that the TGFβ3-Smad-HIPK2 pathway is important for the survival of dopami‐
nergic neurons during development [96,230]. However, recently, a very specific and important
role of Smad3 for the nigrostriatal system was explored in a Smad3 null mouse model
representing an exciting model of PD [231]. These animals show a reduced number of
dopaminergic neurons in the rostral SN, resulting from a postnatal neurodegenerative process.
The selective pro-survival effect of Smad3 for SN dopaminergic neurons was emphasized by
stereological quantifications showing no alterations of the striatal neuronal number. In Smad3
null mice a diminished trophic support provided by Erk1/2 signalling and a reduced astrocytic
support to nigral dopaminergic neurons was detected [231]. Though striatal dopamine levels
were not changed in Smad3 null mice, a strong increase of DA metabolism, including elevated
monoamine-oxidase (MAO) levels were identified, resembling PD findings [232]. Finally,
increased expression and aggregation of α-syn in neurites and cell bodies of several telence‐
phalic, mesencephalic and rombencephalic brain regions and in fibres of the primary and
secondary motor cortex were found [231]. Two possible functional Smad3-based circuits are
suggested. Either Smad3 might directly regulate the α-syn transcription, which further allows
modulating DA metabolism, or the Smad3 deficiency caused elevated DA catabolism gener‐
ates oxidative stress which allow toxic aggregation of α-syn. The data qualify Smad3 as a
possible target for PD therapy. Interestingly, the currently pursued target to re-implant
dopaminergic neurons is also based on modification of Smad signalling during their in vitro
establishment [130,233].
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4.3. Motor neuron diseases
As mentioned above, Smads are essentially controlling the plasticity of NMJ, the intra-axonal
transport and affect axonal repair processes. Accordingly, selective motor neuron diseases
exhibit disturbances of Smad signalling, e.g. spinal muscular atrophy, [234], spinal bulbar
muscular atrophy [235] or amyotrophic lateral sclerosis (ALS).
ALS is a progressive neurodegenerative disease, which targets upper and lower motor
neurons. In the primary motor cortex and the anterior horn of the spinal cord, motor neurons
disappear and the pyramidal tract degenerates [236-238]. The remaining motor neurons exhibit
inclusion bodies e.g. Bunina bodies, hyaline and skein-like inclusions. The pathological
transactive response DNA-binding protein with a molecular weight of 43 kDa (TDP-43) was
shown to be the major disease protein in ALS. Recently, increased nuclear immunoreactivity
for pSmad2,3 in motor neurons was reported from sporadic ALS patients in spinal cord [239].
Motor neurons, where a colocalization of TDP-43 and pSmad2,3 in skeine-like and round
hyaline inclusions was detected [239], show reduced nuclear pSmad2,3 immunoreactivity
[240]. Obviously a disruption of Smad signalling by Smad segregation, comparable to AD or
several tauopathies, enhances the loss of motor neuron function. Smad4 seems actively
involved in the control of motor function as targeted disruption of Smad4 demonstrates [132].
Probably, increased nuclear pSmad2,3 content in the remaining ALS motor neurons indicates
an endogenously initiated approach to a functional improvement. Experiments with an ALS
mouse model support this hypothesis, because TGFβ2 administration ameliorated the motor
performance of the mice [241]. A reduction of TDP-43 containing aggregates by Smad2
overexpression confirms in vitro a protective role of activated Smad signalling in ALS [242].
In summary, initiation and/or progression of many neurological disorders are directly linked
to altered Smad signalling, comprising cytoplasmic Smad aggregation/sequestration, and
nuclear reduction, disruption of transcriptional machinery and stimulating proapoptotic
signalling, therefore disturbing biological processes, which are essential for all phases of
nervous system development and homeostasis.
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